Key Clinical Points Prostate-Cancer Screening The introduction of prostate-specific antigen
(PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer …

Abstract Background In the United States, Black men are at highest risk for being diagnosed
with and dying from prostate cancer. Given this disparity, we examined relevant data to …

Objective To summarise and compare the key recommendations on prostate-specific
antigen (PSA)-based screening for prostate cancer, and so highlight where more evidence …

Context Prostate‐specific antigen (PSA) testing increases prostate cancer diagnoses and
reduces long‐term disease‐specific mortality, but also results in overdiagnoses and …

In 2023, nearly 2 million Americans will be diagnosed with cancer, and 610,000 will die from
it. 1 Cancer is the leading cause of death in persons younger than 85 years 2 and the …

Decisions around prostate-specific antigen screening require a patient-centred approach,
considering the benefits and risks of potential harm. Using shared decision-making (SDM) …

Objective The aim of this study is to evaluate the effectiveness of web-based decision aids
(WDAs) on cancer-related clinical care in terms of different decision categories and by …

Although there are several decision aids for the treatment of localized prostate cancer (PCa),
there are limitations in the consistency and certainty of the information provided. We aimed …

Importance This randomized clinical trial examines the feasibility and acceptability of a
decision-making tool for increasing patient interest in individualized recommendations for …

Abstract Purpose of Review We summarize the evidence of benefits, harms, and tools to
assist in individualized decisions among older adults in screening for breast, prostate, colon …